Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials
Nivashnee Naicker, Anushka Naidoo, Lise Werner, Nigel Garrett, Nelisile Majola, Villeshni Asari, Cheryl Baxter, Anneke Grobler, Quarraisha Abdool Karim, Salim S Abdool Karim
ANTIVIRAL THERAPY | INT MEDICAL PRESS LTD | Published : 2017
BACKGROUND: We assessed whether women who acquired HIV during tenofovir gel prophylaxis trials can be safely and effectively treated with tenofovir-containing antiretroviral therapy (ART). METHODS: Between May 2011 and October 2014, HIV seroconvertors from two tenofovir gel trials were recruited when eligible for ART (CD4+ T-cell count <350 cells/μl, pregnancy or AIDS-defining illness). Women were randomized to tenofovir-containing (tenofovir + lamivudine/emtricitabine + efavirenz) or tenofovir-sparing (zidovudine + lamivudine/emtricitabine + efavirenz) antiretroviral treatment regimens. The proportion with virological suppression, adverse events and drug switches were compared. RESULTS: Fif..View full abstract
Awarded by US Department of Health and Human Services (DHHS)
Awarded by South African Department of Science and Technology
Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
CAPRISA was established as part of the Comprehensive International Program of Research on AIDS (CIPRA) of the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH), US Department of Health and Human Services (DHHS; grant number 5U19 AI051794). The CAPRISA 009 study was funded by the South African Department of Science and Technology (grant number DST/CON 0216/2011).